Compare VanEck Rare Earth/Strategic Metals (REMX) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Rare Earth/Strategic Metals vs Repligen Corporation Common Stock — how do they compare? VanEck Rare Earth/Strategic Metals trades at $54.33 (market cap $1.64B), while Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B). The key difference: Repligen Corporation Common Stock is far larger — about 6.9× VanEck Rare Earth/Strategic Metals's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, VanEck Rare Earth/Strategic Metals nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Rare Earth/Strategic Metals for 52 Days and Repligen Corporation Common Stock for 0 Days on average.
| REMX | RGEN | |
|---|---|---|
Market Cap | $1.64B | $11.31B |
Volume | 811,448 | 1,216,919 |
Sector | Sector/Thematic | Health |
52-Week High | $109.53 | $194.57 |
52-Week Low | $55.78 | $102.87 |
Typical Hold Time | 52 Days | 0 Days |
Enterprise Value | — | $11.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
REMX (VanEck Rare Earth and Strategic Metals ETF) trades at $57.45, down 1.25% with bearish technical signals from moving averages but bullish oscillators. The ETF faces sector volatility amid shifting rare earth market dynamics, with recent news highlighting geopolitical tensions and supply chain developments. Financial ratios remain unavailable for this diversified fund structure.
The rare earth sector faces both opportunity from supply chain diversification efforts and risk from China's market dominance. While strategic importance supports long-term demand, high volatility and concentrated exposure require careful risk management for investors considering this thematic ETF.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Rare Earth/Strategic Metals
REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
